An evaluation is currently taking place of the legislation for medicines for special populations, including both children and rare diseases. This evaluation will assess the efficiency and effectiveness of the current European Union (EU) legislation following recent pharmaceutical developments, particularly recent incentives for research, development and marketing of children’s and rare disease medicines. The outcomes of the evaluation will help to shape the EU policy on medicines for these special populations.
The public consultation feedback period for interested parties to share their views on the legislation is open from 12 October 2018 to 04 January 2019.
MAP would like to emphasise the need for wide ranges of input on this consultation. There is, as ever, a risk that the views of experts in the industry are not heard, as this consultation is aimed at individuals. Therefore, pharma and health professionals are particularly encouraged to comment, doing so as citizens rather than as company representatives.